Company intelligence / Profile preview
GI Biome Co., Ltd.
- Ownership
- Private
- Development stage
- Phase 1
Overview
GI Biome Co., Ltd. develops synbiotic-based therapies targeting the human gut microbiota to treat a range of chronic and incurable diseases. The company collaborates with leading academic institutions for new drug development. It has at least two programs in clinical trials focused on innovative approaches combining probiotics/prebiotics with other modalities for conditions like solid tumors, NAFLD/NASH, and Crohn’s disease. No published late-stage or commercial results yet.[1][2]
- Therapeutic areas
- OtherGastroenterology
- Modalities
- Synbiotics (combination of probiotics and prebiotics)microbiome-based therapies[2]
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on GI Biome Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GI Biome Co., Ltd..